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Monday, March 7, 2011 215amechanisms. Since growing crystals of large complexes that are heteroge-
neously glycosylated like the HA/SP-D or HA/SP-A complexes is difficult,
we have undertaken computational studies to model the interactions. Crystal
structures of HA, SP-A, and SP-D with small saccharide ligands offer starting
points for modeling full length complex type or high-mannose glycosylation
using low energy sugar chain conformations derived from solution studies. Fur-
ther computational approaches are used to obtain an ensemble of potential com-
plex structures. Analysis of these structures can give insights into the
mechanisms of inhibition of SP-D and SP-A variants, as well as the specificity
of SP-D and SP-A for certain glycoforms of HA. Measurement of the differ-
ences in glycosylation site occupation and the glycans residing on HA and
SP-A or SP-D is an important adjunct to the molecular modeling. A complete
strategy based on liquid chromatography/tandem mass spectrometry analysis is
underway to investigate the different glycosite and glycoforms present.
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Protein-protein interactions (PPI) are fundamental to almost all biological and
pathological processes and therefore represent an important class of therapeutic
targets that can be utilized against multi-drug resistant pathogens such as HIV-
1. The HIV-1 capsid (CA) protein has recently emerged as an attractive target
as it performs essential roles, both regulatory and structural in early and late
stages of the viral life cycle. Hence, small-molecule inhibitors of capsid assem-
bly would be attractive and novel antiretroviral medications. With the latest
crystal structure of the hexameric arrangement of CA monomers, atomic level
details of the CA hexamer interface are now available. The HIV-1 capsid shell
is composed of ~250 CA hexamers and 12 CA pentamers which are arranged in
the form of a fullerene cone. Crystal structure analysis shows a weak associa-
tion between the monomers and hence the interfaces formed between the N-ter-
minal (NTD) and C-terminal domains (CTD) seem attractive as drug targets. In
this study, we targeted the NTD-NTD interface region as a novel PPI to design
inhibitors using the hybrid structure based method. Our preliminary results
show that we have identified two compounds (CK026 and CK422) that display
significant antiretroviral activity against HIV-1. Importantly, these compounds
belong to two distinct inhibitory classes: early-stage inhibitors and late-stage
inhibitors. Compound CK026 represents the first CA-targeted small molecule
that works by disruption of pre-integration events in HIV-1 replication. Further
chemical modification has led to identification of other analogs that retain the
antiviral activity with improved drug like properties.
1174-Pos Board B84
Protein Loop Modeling using Distance-Guided Sequential Monte Carlo
Method
Ke Tang, Jinfeng Zhang, Jie Liang.
Modeling loop regions is an important task for protein structure prediction.
We have developed a new loop construction method through efficient sam-
pling with a loop-specific energy function. Based on a new sequential Monte
Carlo sampling strategy called Distance-guided Sequential Monte Carlo
(dSMC), our method efficiently generate loop conformations with lower en-
ergy. To derive the loop-specific energy function, a decoy-based reference
state is used with a large set of loop conformations. Our approach is works
well in modeling long loops. The average smallest global RMSD for 11 res-
idue loops generated is about 1.5 A. Our method also addresses the challeng-
ing problem of multi-loop modeling. As loops often are in spatial proximity
and interact with each other, our approach treats these loops simultaneously
and sample multiple loop efficiently. As an example, for the protein ribonucle-
ase A (PDB id: 7RSA) which has 3 loops (7þ4þ5 residues), the global RMSD
for the loops with the lowest energy compared to the known structure is only
0.52 A.
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Mitochondrial aldehyde dehydrogenase (ALDH2) is an enzyme that partici-
pates in multiple metabolic pathways, including the oxidation of toxic biogenic
and environmental aldehydes. Our laboratory is interested in developing novel
and selective ALDH2 inhibitors. We recently identified and studied three dis-
tinct classes of small molecules based on their ability to inhibit ALDH2 activity
(esterase, dehydrogenase, and both). These inhibitors were identified by virtual
screen which consisted of three steps: 1) docking 800,000 ChemBridge mole-cules to the substrate cavity in ALDH2; 2) scoring the receptor-ligand com-
plexes while computing the binding affinity; and 3) ranking the top 1,000
compounds using GlideScore to determine the top 250 compounds for study.
From this list, 112 compounds were selected for purchase and screened for in-
hibitory activity at 50 uM. 19 compounds were selected for further evaluation
based on their ability to inhibit hALDH2 propionaldehyde oxidation by more
than 60%. IC50 values for these compounds were determined using both the
dehydrogenase and esterase assays.
We selected 4 compounds with IC50 values less than 20uM for further kinetic
and structural studies: I32, I72, I76, and I78. These inhibitors show a competi-
tive inhibition pattern toward varied NADþ concentrations and either uncom-
petitive or noncompetitive inhibition towards varied priopionaldehyde
concentrations. Based on their structural similarity and x-ray crystallography
structures obtained with these compounds bound to the enzyme, fragments
were then chosen for studying the mechanism by which they inhibit ALDH2.
The next step is to solve the structures of these fragments bound to ALDH2
and develop SAR data for fragment based compound development that will en-
hance their specificity for and inhibition of ALDH2. This work was supported
by NIH R01-AA18123 and NIH R01-AA18123S1.
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Predicting accurate ligand poses and ligand selective receptor conformations
are imperative in designing efficacious, functionally specific drugs for G-pro-
tein coupled receptors. Comparison of the crystal structures of carazolol (in-
verse agonist), formoterol(agonist), and agonist with G-protein mimic bound
b2 Adrenergic Receptor (b2AR) shows that the agonist stabilizes a slightly dif-
ferent conformation when there is no G-protein bound. The G-protein bound
receptor state exhibits a high affinity conformation for the agonist. Using the
computational method LITiCon, we have calculated the activation pathways
for full, partial and inverse agonists of b2AR, which are in agreement with fluo-
rescence intensity lifetime measurements. MD simulations starting from vari-
ous conformations along the activation pathway (total ~1.5 ms) show that in
the absence of G protein, norepinephrine (agonist) stabilizes an intermediate re-
ceptor state that is similar to the formoterol bound intermediate state without
the G-protein, in agreement with the recent crystal structure of formoterol
bound b2AR. Thus coupling to G protein may be needed for stabilizing the
fully active state.
Using Liticon method we have calculated the activation pathway of agonist
bound adenosine receptor A2A starting from its inactive state. We found that
water plays a important role in the docking of the antagonist as well as the ag-
onist.
We recently predicted the structures of D3 dopamine receptor and CXCR4 che-
mokine receptor as part of the competition for the assessment of computational
methods in GPCR modeling (GPCR Dock 2010). The predicted docked poses
of both the ligands are in close agreement with the crystal structures. The de-
tails of the methods and comparison with the crystal structures will be pre-
sented.
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Biophysical Approaches to Discovery of Novel Antibacterial Leads
Gautam Sanyal.
This presentation will outline biophysical approaches to discovery of antibac-
terial lead compounds that are designed to address bacterial resistance to many
current antibiotics. There are a number of essential enzymes, in key pathways
of pathogenic bacteria, which have not been targeted by existing drugs. The po-
tential bacterial selectivity and spectrum of these single gene targets can be val-
idated using structural tools. In addition, inhibiting clinically exploited and
validated bacterial enzymes with a different mechanism (e.g., at a different
binding site) than those offered by current drugs can be a powerful approach.
Target enzymes that have remained unexploited or those that offer alternative
binding sites include cell wall biosynthesis and DNA replication enzymes. In
our discovery efforts, biophysical studies including X-ray crystallography
and NMR spectroscopy are utilized at all stages of lead generation beginning
with target selection, validation, selectivity analysis and probing of target bind-
ing sites for druggability. This will be exemplified with comparative structures
of target enzymes from different pathways. Hits identified through screening of
compound and fragment libraries against these targets are progressed towards
leads with the help of biophysical and structural analysis of protein-ligand com-
plexes. Development of effective screening assays for enzyme targets requires
a thorough understanding of enzyme mechanism. An example will be given of
how water LOGSYmeasurements by NMR explained the mechanism of a mul-
tisubstrate cell wall enzyme. Finally, development of a lead series against
